DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer

Phase 1/2 Terminated 22 enrolled Memorial Sloan Kettering Cancer Center

NaSequentialOpen-labelTreatment

Summary

This study will test the safety of the study drug, DS-3201b, given in combination with irinotecan to people who have recurrent small cell lung cancer (SCLC).

Timeline

Start: 2019-03-15
Primary completion: 2023-05-02
Completion: 2023-05-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Valemetostat	Small molecule	100 mg	—
Background	Irinotecan	Small molecule	125 mg/m2	Intravenous

DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer

Summary

Timeline

Drugs

Indications